Genetic data and cognitively defined late-onset Alzheimer's disease subgroups
- PMID: 30514930
- PMCID: PMC6548676
- DOI: 10.1038/s41380-018-0298-8
Genetic data and cognitively defined late-onset Alzheimer's disease subgroups
Erratum in
-
Correction: Genetic data and cognitively defined late-onset Alzheimer's disease subgroups.Mol Psychiatry. 2020 Nov;25(11):3100. doi: 10.1038/s41380-019-0348-x. Mol Psychiatry. 2020. PMID: 30647434 Free PMC article.
Abstract
Categorizing people with late-onset Alzheimer's disease into biologically coherent subgroups is important for personalized medicine. We evaluated data from five studies (total n = 4050, of whom 2431 had genome-wide single-nucleotide polymorphism (SNP) data). We assigned people to cognitively defined subgroups on the basis of relative performance in memory, executive functioning, visuospatial functioning, and language at the time of Alzheimer's disease diagnosis. We compared genotype frequencies for each subgroup to those from cognitively normal elderly controls. We focused on APOE and on SNPs with p < 10-5 and odds ratios more extreme than those previously reported for Alzheimer's disease (<0.77 or >1.30). There was substantial variation across studies in the proportions of people in each subgroup. In each study, higher proportions of people with isolated substantial relative memory impairment had ≥1 APOE ε4 allele than any other subgroup (overall p = 1.5 × 10-27). Across subgroups, there were 33 novel suggestive loci across the genome with p < 10-5 and an extreme OR compared to controls, of which none had statistical evidence of heterogeneity and 30 had ORs in the same direction across all datasets. These data support the biological coherence of cognitively defined subgroups and nominate novel genetic loci.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures


References
-
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44. doi: 10.1212/WNL.34.7.939. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG052521/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- U01 AG068057/AG/NIA NIH HHS/United States
- R01 AG017917/AG/NIA NIH HHS/United States
- U01 AG006781/AG/NIA NIH HHS/United States
- K23 AG046377/AG/NIA NIH HHS/United States
- R01 AG030653/AG/NIA NIH HHS/United States
- P30 AG066468/AG/NIA NIH HHS/United States
- R01 AG041718/AG/NIA NIH HHS/United States
- R43 AG042904/AG/NIA NIH HHS/United States
- R01 AG015819/AG/NIA NIH HHS/United States
- R56 AG057191/AG/NIA NIH HHS/United States
- R01 AG064877/AG/NIA NIH HHS/United States
- U01 HG006375/HG/NHGRI NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- R01 AG019771/AG/NIA NIH HHS/United States
- U01 AG032984/AG/NIA NIH HHS/United States
- K01 AG050699/AG/NIA NIH HHS/United States
- R01 AG030146/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- K25 AG055620/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- R01 AG029672/AG/NIA NIH HHS/United States
- U19 AG024904/AG/NIA NIH HHS/United States
- R01 AG042437/AG/NIA NIH HHS/United States
- CIHR/Canada
- P30 AG010161/AG/NIA NIH HHS/United States
- R44 AG042904/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States